Results 161 to 170 of about 4,813,932 (329)
Molecular Oncology, EarlyView.AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
On the convergence of continued fractions at Runckel's points and the Ramanujan conjecture
, 2004 We consider the limit periodic continued fractions of Stieltjes $$ \frac{1}{1-} \frac{g_1 z}{1-} \frac{g_2(1-g_1) z}{1-} \frac{g_3(1-g_2)z}{1-...,}, z\in \mathbb C, g_i\in(0,1), \lim\limits_{i\to \infty} g_i=1/2, \quad (1) $$ appearing as Shur--Wall $g ...
Tsygvintsev, Alexei
core +1 more source
Differentiation of a human eosinophilic leukemia cell line (EoL-1) by a human T-cell leukemia cell line (HIL-3)-derived factor [PDF]
, 1991 Masashi Morita +9 more
openalex +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Radio and γ-ray loud narrow-line Seyfert 1 galaxies in the spotlight [PDF]
, 2016 V. Karamanavis +5 more
openalex +1 more source
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular Oncology, EarlyView.Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source